Ischemic Stroke - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 281 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ischemic Stroke - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Ischemic Stroke - Pipeline Review, H1 2015’, provides an overview of the Ischemic Stroke’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ischemic Stroke
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ischemic Stroke and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ischemic Stroke
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ischemic Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Ischemic Stroke Overview 10
Therapeutics Development 11
Pipeline Products for Ischemic Stroke - Overview 11
Pipeline Products for Ischemic Stroke - Comparative Analysis 12
Ischemic Stroke - Therapeutics under Development by Companies 13
Ischemic Stroke - Therapeutics under Investigation by Universities/Institutes 19
Ischemic Stroke - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Ischemic Stroke - Products under Development by Companies 24
Ischemic Stroke - Products under Investigation by Universities/Institutes 29
Ischemic Stroke - Companies Involved in Therapeutics Development 30
AB Science 30
Acorda Therapeutics, Inc. 31
Acticor Biotech 32
advanceCor GmbH 33
AGY Therapeutics, Inc. 34
Angion Biomedica Corp. 35
AstraZeneca PLC 36
Athersys, Inc. 37
Biogen Idec Inc. 38
BioTime, Inc. 39
Cetazam Therapeutics LLC 40
Concert Pharmaceuticals, Inc. 41
D-Pharm Ltd. 42
Daiichi Sankyo Company, Limited 43
DiaMedica Inc. 44
Digna Biotech, S.L. 45
Genervon Biopharmaceuticals, LLC 46
GlaxoSmithKline plc 47
Glucox Biotech AB 48
Grifols, S.A. 49
Huons Co., Ltd. 50
International Stem Cell Corporation 51
Laboratoires Pierre Fabre SA 52
Lumosa Therapeutics Co., Ltd. 53
MediaPharma s.r.l. 54
Mesoblast Limited 55
Mitsubishi Tanabe Pharma Corporation 56
Neuralstem, Inc. 57
Neurotec Pharma SL 58
NeuroVive Pharmaceutical AB 59
Panacea Pharmaceuticals, Inc. 60
Pharmicell Co., Ltd. 61
PhytoHealth Corporation 62
Pluristem Therapeutics Inc. 63
Regado Biosciences, Inc. 64
Remedy Pharmaceuticals, Inc. 65
ReNeuron Group plc 66
SanBio, Inc. 67
Saneron CCEL Therapeutics, Inc. 68
Simcere Pharmaceutical Group 69
Stemedica Cell Technologies, Inc. 70
Stempeutics Research Private Limited 71
SynZyme Technologies, LLC 72
Tenax Therapeutics, Inc. 73
Vicore Pharma AB 74
Virogenomics, Inc. 75
Ischemic Stroke - Therapeutics Assessment 76
Assessment by Monotherapy Products 76
Assessment by Target 77
Assessment by Mechanism of Action 80
Assessment by Route of Administration 83
Assessment by Molecule Type 85
Drug Profiles 87
3K3A-APC - Drug Profile 87
AB-144 - Drug Profile 89
ACT-017 - Drug Profile 90
Aptamers for Cardiovascular Diseases - Drug Profile 91
BB-3 - Drug Profile 92
BSc-2118 - Drug Profile 94
C-10068 - Drug Profile 95
C-21 - Drug Profile 96
Cerecellgram-Stroke - Drug Profile 98
CET-101 - Drug Profile 99
CNB-001 - Drug Profile 100
dalfampridine ER - Drug Profile 102
DB-017 - Drug Profile 104
DM-199 - Drug Profile 105
Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile 106
DS-1040 - Drug Profile 107
glyburide - Drug Profile 108
GM-602 - Drug Profile 110
GSK-249320 - Drug Profile 111
GXNPC-1 - Drug Profile 113
HBN-1 - Drug Profile 114
HU-010 - Drug Profile 115
Human Plasmin - Drug Profile 116
Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile 118
levomilnacipran hydrochloride ER - Drug Profile 121
LT-3001 - Drug Profile 123
Lysimab - Drug Profile 124
masitinib - Drug Profile 125
Memantine Nitrone - Drug Profile 128
Mesenchymal Stem Cells - Drug Profile 129
Monoclonal Antibody for Cardiovascular and Ischemic Stroke - Drug Profile 131
MP-124 - Drug Profile 132
MPHE-001A - Drug Profile 133
MultiStem - Drug Profile 134
natalizumab - Drug Profile 137
NSI-566 - Drug Profile 139
NTKC-005 - Drug Profile 141
NVP-014 - Drug Profile 142
NVX-208 - Drug Profile 143
Oxycyte - Drug Profile 144
PAN-811 - Drug Profile 146
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile 148
PHN-014 - Drug Profile 149
phycocyanobilin - Drug Profile 150
Pinocembrin - Drug Profile 151
Polyglactin 370 for Ischemic Stroke - Drug Profile 152
PR-15 - Drug Profile 153
prasugrel hydrochloride - Drug Profile 155
Protein for Ischemic Stroke - Drug Profile 158
Protein for Ischemic Stroke - Drug Profile 159
Protein for Ischemic Stroke - Drug Profile 160
Recombinant Peptide for Ischemic Cerebral Stroke - Drug Profile 161
Recombinant Plasmin - Drug Profile 163
Recombinant Protein for Ischemic Cerebral Stroke - Drug Profile 164
Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile 165
ReN-001 - Drug Profile 166
RTL-551 - Drug Profile 167
SB-623 - Drug Profile 168
SIM-071201 - Drug Profile 169
Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile 170
Small Molecule to Block Sodium Channels for Ischemic Stroke - Drug Profile 171
Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 172
Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 173
Small Molecules for Brain Ischemia and Ischemic Stroke - Drug Profile 174
Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile 175
Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile 176
Small Molecules to Inhibit AGY-207 for Ischemic Stroke - Drug Profile 177
Small Molecules to Inhibit AGY-221 for Ischemic Stroke - Drug Profile 178
Small Molecules to Inhibit CaMKII for Ischemic Stroke - Drug Profile 179
Small Molecules to Inhibit Cysteine Protease for Ischemic Stroke - Drug Profile 180
Small Molecules to Inhibit Kinase for Ischemic Stroke - Drug Profile 181
Small Molecules to Inhibit Protein Kinase for Ischemic Stroke - Drug Profile 182
SMTP-7 - Drug Profile 183
Stem Cell Therapy for Ischemic Stroke - Drug Profile 184
Stem Cell Therapy for Liver Insufficiency, Acute Ischemic Stroke and Tibial Fractures - Drug Profile 185
Stem Cell Therapy for Parkinson Disease and Ishemia Stroke - Drug Profile 186
Stem Cell Therapy for Parkinson’s Disease, Traumatic Brain Injury and Stroke - Drug Profile 187
Stempeucel - Drug Profile 189
StromAb - Drug Profile 192
T-33 - Drug Profile 193
THR-18 - Drug Profile 194
ticagrelor - Drug Profile 195
TPAi-14 - Drug Profile 199
TPAi-23 - Drug Profile 200
TXA-127 - Drug Profile 201
TXA-302 - Drug Profile 203
VACNO - Drug Profile 205
Ischemic Stroke - Recent Pipeline Updates 206
Ischemic Stroke - Dormant Projects 260
Ischemic Stroke - Discontinued Products 264
Ischemic Stroke - Product Development Milestones 267
Featured News & Press Releases 267
Appendix 274
Methodology 274
Coverage 274
Secondary Research 274
Primary Research 274
Expert Panel Validation 274
Contact Us 274
Disclaimer 275

List of Tables

Number of Products under Development for Ischemic Stroke, H1 2015 17
Number of Products under Development for Ischemic Stroke - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 20
Number of Products under Development by Companies, H1 2015 (Contd..1) 21
Number of Products under Development by Companies, H1 2015 (Contd..2) 22
Number of Products under Development by Companies, H1 2015 (Contd..3) 23
Number of Products under Development by Companies, H1 2015 (Contd..4) 24
Number of Products under Investigation by Universities/Institutes, H1 2015 26
Comparative Analysis by Late Stage Development, H1 2015 27
Comparative Analysis by Clinical Stage Development, H1 2015 28
Comparative Analysis by Early Stage Development, H1 2015 29
Products under Development by Companies, H1 2015 30
Products under Development by Companies, H1 2015 (Contd..1) 31
Products under Development by Companies, H1 2015 (Contd..2) 32
Products under Development by Companies, H1 2015 (Contd..3) 33
Products under Development by Companies, H1 2015 (Contd..4) 34
Products under Investigation by Universities/Institutes, H1 2015 35
Ischemic Stroke - Pipeline by AB Science, H1 2015 36
Ischemic Stroke - Pipeline by Acorda Therapeutics, Inc., H1 2015 37
Ischemic Stroke - Pipeline by Acticor Biotech, H1 2015 38
Ischemic Stroke - Pipeline by advanceCor GmbH, H1 2015 39
Ischemic Stroke - Pipeline by AGY Therapeutics, Inc., H1 2015 40
Ischemic Stroke - Pipeline by Angion Biomedica Corp., H1 2015 41
Ischemic Stroke - Pipeline by AstraZeneca PLC, H1 2015 42
Ischemic Stroke - Pipeline by Athersys, Inc., H1 2015 43
Ischemic Stroke - Pipeline by Biogen Idec Inc., H1 2015 44
Ischemic Stroke - Pipeline by BioTime, Inc., H1 2015 45
Ischemic Stroke - Pipeline by Cetazam Therapeutics LLC, H1 2015 46
Ischemic Stroke - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 47
Ischemic Stroke - Pipeline by D-Pharm Ltd., H1 2015 48
Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 49
Ischemic Stroke - Pipeline by DiaMedica Inc., H1 2015 50
Ischemic Stroke - Pipeline by Digna Biotech, S.L., H1 2015 51
Ischemic Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2015 52
Ischemic Stroke - Pipeline by GlaxoSmithKline plc, H1 2015 53
Ischemic Stroke - Pipeline by Glucox Biotech AB, H1 2015 54
Ischemic Stroke - Pipeline by Grifols, S.A., H1 2015 55
Ischemic Stroke - Pipeline by Huons Co., Ltd., H1 2015 56
Ischemic Stroke - Pipeline by International Stem Cell Corporation, H1 2015 57
Ischemic Stroke - Pipeline by Laboratoires Pierre Fabre SA, H1 2015 58
Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2015 59
Ischemic Stroke - Pipeline by MediaPharma s.r.l., H1 2015 60
Ischemic Stroke - Pipeline by Mesoblast Limited, H1 2015 61
Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 62
Ischemic Stroke - Pipeline by Neuralstem, Inc., H1 2015 63
Ischemic Stroke - Pipeline by Neurotec Pharma SL, H1 2015 64
Ischemic Stroke - Pipeline by NeuroVive Pharmaceutical AB, H1 2015 65
Ischemic Stroke - Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 66
Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H1 2015 67
Ischemic Stroke - Pipeline by PhytoHealth Corporation, H1 2015 68
Ischemic Stroke - Pipeline by Pluristem Therapeutics Inc., H1 2015 69
Ischemic Stroke - Pipeline by Regado Biosciences, Inc., H1 2015 70
Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 71
Ischemic Stroke - Pipeline by ReNeuron Group plc, H1 2015 72
Ischemic Stroke - Pipeline by SanBio, Inc., H1 2015 73
Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H1 2015 74
Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2015 75
Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H1 2015 76
Ischemic Stroke - Pipeline by Stempeutics Research Private Limited, H1 2015 77
Ischemic Stroke - Pipeline by SynZyme Technologies, LLC, H1 2015 78
Ischemic Stroke - Pipeline by Tenax Therapeutics, Inc., H1 2015 79
Ischemic Stroke - Pipeline by Vicore Pharma AB, H1 2015 80
Ischemic Stroke - Pipeline by Virogenomics, Inc., H1 2015 81
Assessment by Monotherapy Products, H1 2015 82
Number of Products by Stage and Target, H1 2015 84
Number of Products by Stage and Mechanism of Action, H1 2015 87
Number of Products by Stage and Route of Administration, H1 2015 90
Number of Products by Stage and Molecule Type, H1 2015 92
Ischemic Stroke Therapeutics - Recent Pipeline Updates, H1 2015 212
Ischemic Stroke - Dormant Projects, H1 2015 266
Ischemic Stroke - Dormant Projects (Contd..1), H1 2015 267
Ischemic Stroke - Dormant Projects (Contd..2), H1 2015 268
Ischemic Stroke - Dormant Projects (Contd..3), H1 2015 269
Ischemic Stroke - Discontinued Products, H1 2015 270
Ischemic Stroke - Discontinued Products (Contd..1), H1 2015 271
Ischemic Stroke - Discontinued Products (Contd..2), H1 2015 272